Skip to content

SYMPATHY: Renal sympathetic denervation as a new treatment for therapy resistant hypertension.

SYMPATHY: Renal sympathetic denervation as a new treatment for therapy resistant hypertension. - SYMPATHY

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON39831
Enrollment
570
Registered
2013-03-12
Start date
2013-05-23
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertensie high blood pressure hypertension

Interventions

Bilateral renal denervation, using radiofrequency energy delivered to the renal arterial walls via an intra-arterial catheter.

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1.Individual has an average 24-hour SBP of >= 130 mmHg or a mean day-time SBP >= 135 mmHg, as determined with the use of ABPM, while the patient uses 3 or more antihypertensive agents or with documented intolerance to 2 or more of the 4 major classes antihypertensive drugs (ACE/ARB, Calcium channel blocker, Beta Blocker, Diuretic) and no possibility to take 3 anti-hypertensive drugs. 2.Individual is >=18 years of age.

Exclusion criteria

Exclusion criteria: 1.Individual has a treatable secondary cause of hypertension 2.Individual has an eGFR below 1. Individual has a treatable secondary cause of hypertension 3.Individual has renal artery anatomy that is ineligible for treatment

Design outcomes

Primary

MeasureTime frame
The primary endpoint: change in ABPM (24-h or average day-time SBP).

Secondary

MeasureTime frame
Key secondary study parameters/endpoints: 1)Change in the amount of antihypertensive medication (daily defined dose). 2) The effect of RD in subgroups: across strata of eGFR (eGFR 20-60 mL/min per 1.73m2 and eGFR>60 mL/min per 1.73m2) and across strata of baseline BP (SBP 140-160mmHg and >160mmHg). 3)Change in office BP.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)